Introduction: Chemotherapy-induced peripheral neuropathies (CIPN) are a dose-limiting
adverse effect of certain anticancer drugs (platinum salts, vinca alkaloids, taxanes, bortezomib, …

Neurotoxicity remains the most common adverse effect of oxaliplatin, limiting its clinical use.
In the present study, we developed a mouse model of chronic oxaliplatin-induced …

Oxaliplatin, the first-line chemotherapeutic agent against colorectal cancer (CRC), induces
peripheral neuropathies, which can lead to dose limitation and treatment discontinuation. …

Diabetic neuropathy is often associated with chronic pain. Serotonin type 6 (5-HT 6 ) receptor
ligands, particularly inverse agonists, have strong analgesic potential and may be new …

Peripheral neuropathy is the most frequent dose-limiting adverse effect of oxaliplatin. Acute
pain symptoms that are induced or exacerbated by cold occur in almost all patients …

Background The incidence of cardiovascular diseases is increasing in persons with
hemophilia A (HA). Therefore, anticoagulant therapy based on direct oral anticoagulants (DOACs) …

Cav3. 2 T-type calcium channel is a major molecular actor of neuropathic pain in peripheral
sensory neurons, but its involvement at the supraspinal level is almost unknown. In the …

Identifying compounds that are neurotoxic either toward the central or the peripheral nervous
systems (CNS or PNS) would greatly benefit early stages of drug development by derisking …

The diverse signaling pathways engaged by serotonin type 6 receptor (5-HT 6 R) together
with its high constitutive activity suggests different types of pharmacological interventions for …

Persistent inflammation and persistent pain are major medical, social and economic
burdens. As such, related pharmacotherapy needs to be continuously improved. The peptide …